QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NYSE:ADCT

ADC Therapeutics (ADCT) Stock Price, News & Analysis

$4.63
-0.23 (-4.73%)
(As of 03/4/2024 ET)
Today's Range
$4.54
$5.27
50-Day Range
$1.60
$5.30
52-Week Range
$0.36
$6.04
Volume
990,014 shs
Average Volume
935,201 shs
Market Capitalization
$355.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33

ADC Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
36.8% Upside
$6.33 Price Target
Short Interest
Healthy
2.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.28mentions of ADC Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.29) to ($1.87) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.34 out of 5 stars

Medical Sector

340th out of 960 stocks

Pharmaceutical Preparations Industry

160th out of 440 stocks


ADCT stock logo

About ADC Therapeutics Stock (NYSE:ADCT)

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBDdimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADCT Stock Price History

ADCT Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Adc Therapeutics SA (ADCT)
ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
RBC Capital Keeps Their Buy Rating on ADC Therapeutics (ADCT)
ADC Therapeutics Provides Business Updates
ADC Therapeutics: Navigating A Swirling Drain
See More Headlines
Receive ADCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/04/2024
Next Earnings (Estimated)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
317
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.33
High Stock Price Target
$9.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+33.1%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-155,800,000.00
Net Margins
-145.64%
Pretax Margin
-148.08%

Debt

Sales & Book Value

Annual Sales
$122.57 million
Book Value
$1.16 per share

Miscellaneous

Free Float
N/A
Market Cap
$365.62 million
Optionable
Optionable
Beta
1.74
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Ameet Mallik M.B.A. (Age 51)
    M.S., CEO & Director
    Comp: $828.96k
  • Mr. Jose I. Carmona M.B.A. (Age 52)
    Chief Financial Officer
  • Dr. Patrick van Berkel Ph.D. (Age 56)
    Chief Scientific Officer
  • Lisa Michelle Kallebo
    Chief Accounting Officer
  • Dr. Michael Mulkerrin Ph.D. (Age 69)
    Chief Technical Operations Officer
  • Amanda Hamilton
    Investor Relations Officer
  • Mr. Peter J. Graham Esq. (Age 57)
    Chief Legal Officer
  • Ms. Eugenia Litz
    Vice President of Investor Relations & Corporate Communications
  • Ms. Kimberly Pope (Age 57)
    Senior VP & Chief People Officer
  • Ms. Kristen Harrington-Smith (Age 51)
    Chief Commercial Officer














ADCT Stock Analysis - Frequently Asked Questions

Should I buy or sell ADC Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADCT, but not buy additional shares or sell existing shares.
View ADCT analyst ratings
or view top-rated stocks.

What is ADC Therapeutics' stock price target for 2024?

5 brokers have issued 12-month target prices for ADC Therapeutics' stock. Their ADCT share price targets range from $2.00 to $9.00. On average, they predict the company's share price to reach $6.33 in the next year. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for ADCT
or view top-rated stocks among Wall Street analysts.

How have ADCT shares performed in 2024?

ADC Therapeutics' stock was trading at $1.66 on January 1st, 2024. Since then, ADCT stock has increased by 178.9% and is now trading at $4.63.
View the best growth stocks for 2024 here
.

Are investors shorting ADC Therapeutics?

ADC Therapeutics saw a drop in short interest in February. As of February 15th, there was short interest totaling 1,430,000 shares, a drop of 51.2% from the January 31st total of 2,930,000 shares. Based on an average daily trading volume, of 925,900 shares, the short-interest ratio is currently 1.5 days. Currently, 2.7% of the shares of the stock are sold short.
View ADC Therapeutics' Short Interest
.

When is ADC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our ADCT earnings forecast
.

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) posted its earnings results on Tuesday, November, 2nd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.01. The business had revenue of $13.15 million for the quarter, compared to the consensus estimate of $7.74 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 1,121.94% and a negative net margin of 145.64%. During the same period in the prior year, the firm posted ($0.29) EPS.

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).

When did ADC Therapeutics IPO?

(ADCT) raised $126 million in an initial public offering on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company served as the underwriters for the IPO.

Who are ADC Therapeutics' major shareholders?

ADC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Goldman Sachs Group Inc. (0.00%), Goldman Sachs Group Inc. (0.00%), Affinity Asset Advisors LLC (0.00%), Saxony Capital Management LLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ADC Therapeutics?

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ADCT) was last updated on 3/4/2024 by MarketBeat.com Staff